Alnylam change to heart drug trial sparks doubts, sinking shares
BioPharma Drive: Drug Pricing
FEBRUARY 15, 2024
Analysts pressed Alnylam executives on the reasons for the changes to HELIOS-B, a Phase 3 study in ATTR amyloidosis with cardiomyopathy that is important to the company’s future.
Let's personalize your content